Literature DB >> 2850759

Amphotericin B encapsulated in liposomes administered to cancer patients.

F Meunier1, J P Sculier, A Coune, C Brassinne, C Heyman, C Laduron, N Collette, C Hollaert, D Bron, J Klastersky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2850759     DOI： 10.1111/j.1749-6632.1988.tb40460.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  9 in total

Review 1.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 2.  Lipid formulations of amphotericin B. Less toxicity but at what economic cost?

Authors:  J Tollemar; O Ringdén
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

Review 3.  Candidiasis.

Authors:  F Meunier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

4.  Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies.

Authors:  A Adedoyin; J F Bernardo; C E Swenson; L E Bolsack; G Horwith; S DeWit; E Kelly; J Klasterksy; J P Sculier; D DeValeriola; E Anaissie; G Lopez-Berestein; A Llanos-Cuentas; A Boyle; R A Branch
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

5.  Successful treatment with liposomal amphotericin B in two patients with persisting fungemia.

Authors:  J P Sculier; D Bron; A Coune; F Meunier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

6.  Treatment of murine cryptococcal meningitis with an SCH 39304-amphotericin B combination.

Authors:  M M Albert; J R Graybill; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 7.  Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.

Authors:  R Janknegt; S de Marie; I A Bakker-Woudenberg; D J Crommelin
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

8.  Comparison of nephrotoxicities of different polyoxyethyleneglycol formulations of amphotericin B in rats.

Authors:  C Tasset; V Preat; A Bernard; M Roland
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 9.  Optimizing efficacy of amphotericin B through nanomodification.

Authors:  Suresh P Vyas; Swati Gupta
Journal:  Int J Nanomedicine       Date:  2006
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.